Princess Margaret Cancer Centre

Toronto V5Z 4E6

11 studies enrolling now · 40 studies all time

What they study most

Accelerated/Blast-phase Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Advanced Solid Tumor, Advanced Solid Tumors, Bladder Cancer, Breast Cancer, Breast Neoplasms, Cancer, Cervical Cancer, Chronic-phase Myelofibrosis, Colorectal Cancer Stage II, Colorectal Cancer Stage III

Studies at this site

• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) — Recruiting now
• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer — Recruiting now
• A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 — Recruiting now
• M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors — Recruiting now
• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors — Recruiting now
• Met Non Small Cell Cancer Registry (MOMENT) — Recruiting now
• Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. — Recruiting now
• Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma — Recruiting now
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation — Recruiting now
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors — Recruiting now
• Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation — Recruiting now
• Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors — Recruiting now
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) — Running, not enrolling
• A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET — Running, not enrolling
• A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia — Running, not enrolling
• A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer — Running, not enrolling
• Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Completed
• Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) — Running, not enrolling
• S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers — Completed
• First in Human Study of M6223 — Completed
• First in Human Study of M1069 in Advanced Solid Tumors — Stopped early
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma — Running, not enrolling
• Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma — Running, not enrolling
• Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma — Completed
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma — Running, not enrolling
• A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface — Completed
• Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — Running, not enrolling
• Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) — Stopped early
• Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma — Completed
• Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma — Stopped early
• Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC — Stopped early
• Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated — Stopped early
• Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation — Completed
• A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation — Running, not enrolling
• A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies — Completed
• Prostate Imaging Using MRI +/- Contrast Enhancement — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma — Completed
• Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML — Stopped early
• M1231 in Participants With Solid Tumors — Completed
• Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma — Status unconfirmed